M

MoonLake Immunotherapeutics
NASDAQ:MLTX

Watchlist Manager
MoonLake Immunotherapeutics
NASDAQ:MLTX
Watchlist
Price: 54.17 USD -0.28% Market Closed
Market Cap: 3.5B USD
Have any thoughts about
MoonLake Immunotherapeutics?
Write Note

MoonLake Immunotherapeutics
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

MoonLake Immunotherapeutics
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
M
MoonLake Immunotherapeutics
NASDAQ:MLTX
Cash & Cash Equivalents
$451.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Cash & Cash Equivalents
$278.6m
CAGR 3-Years
-14%
CAGR 5-Years
15%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash & Cash Equivalents
CHf32.4m
CAGR 3-Years
-30%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash & Cash Equivalents
$225.7m
CAGR 3-Years
-39%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cash & Cash Equivalents
CHf65.7m
CAGR 3-Years
-20%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Xlife Sciences AG
SIX:XLS
Cash & Cash Equivalents
CHf218.7k
CAGR 3-Years
-64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

MoonLake Immunotherapeutics
Glance View

Market Cap
3.4B USD
Industry
N/A

MoonLake Immunotherapeutics is a CH-based company operating in industry. The company is headquartered in Zug, Zug. The company went IPO on 2020-10-20. MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

MLTX Intrinsic Value
7.72 USD
Overvaluation 86%
Intrinsic Value
Price
M

See Also

What is MoonLake Immunotherapeutics's Cash & Cash Equivalents?
Cash & Cash Equivalents
451.2m USD

Based on the financial report for Dec 31, 2023, MoonLake Immunotherapeutics's Cash & Cash Equivalents amounts to 451.2m USD.

What is MoonLake Immunotherapeutics's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 1Y
1 042%

Over the last year, the Cash & Cash Equivalents growth was 1 042%.

Back to Top